Related Experiment Videos
Growth hormone and renal osteodystrophy: a case report
1Michigan State University, College of Human Medicine, Department of Pediatrics/Human Development, East Lansing 48824-1317, USA.
Pediatric Nephrology (Berlin, Germany)
|April 16, 1998
Summary
Recombinant growth hormone treatment in a patient with end-stage renal disease led to severe renal osteodystrophy. Discontinuation of growth hormone therapy resolved the condition, highlighting potential risks in pediatric patients.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Skeletal Biology
Background:
- Adolescent with end-stage renal disease (ESRD) undergoing hemodialysis presented with growth retardation.
- Growth hormone therapy is a potential treatment for growth failure in children with chronic kidney disease.
Observation:
- The patient received recombinant human growth hormone (rhGH) for treatment of growth retardation.
- Following rhGH administration, the patient developed severe renal osteodystrophy.
Findings:
- The severe renal osteodystrophy was refractory to standard treatments.
- Discontinuation of recombinant growth hormone therapy resulted in the resolution of renal osteodystrophy.
Implications:
- This case suggests a potential adverse effect of recombinant growth hormone in pediatric ESRD patients with renal osteodystrophy.
- Careful monitoring for skeletal complications is warranted in children with ESRD treated with growth hormone.
- Further research may be needed to elucidate the mechanism linking growth hormone and renal osteodystrophy in this population.